New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTSPPI, LGNDSpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticalsí (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Check below for free stories on SPPI;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
11:48 EDTSPPISpectrum management to meet with Roth Capital
Subscribe for More Information
September 18, 2014
07:07 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
07:05 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
September 16, 2014
07:02 EDTSPPISpectrum issued new patent for Beleodaq for injection
Spectrum Pharmaceuticals announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8835501, which covers Beleodaq for Injection on September 16, 2014 with patent term adjustment from May 2026 to October 2027. In addition to the existing patent, covering the chemical entity of Beleodaq, this new patent covers the formulation of the product, strengthening and expanding significantly its industrial property protection.
September 9, 2014
09:58 EDTLGNDLigand management to meet with Craig Hallum
Meeting to be held in Milwaukee on September 15 hosted by Craig Hallum.
08:32 EDTLGNDLigand expands license agreement with CURx for Lamotrigine program
Subscribe for More Information
07:01 EDTSPPISpectrum to advance SPI-2013 to Phase 3 trials
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use